Success Metrics

Clinical Success Rate
100.0%

Based on 12 completed trials

Completion Rate
100%(12/12)
Active Trials
1(5%)
Results Posted
42%(5 trials)

Phase Distribution

Ph phase_2
3
15%
Ph phase_3
6
30%
Ph not_applicable
2
10%
Ph phase_4
9
45%

Phase Distribution

0

Early Stage

3

Mid Stage

15

Late Stage

Phase Distribution20 total trials
Phase 2Efficacy & side effects
3(15.0%)
Phase 3Large-scale testing
6(30.0%)
Phase 4Post-market surveillance
9(45.0%)
N/ANon-phased studies
2(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

12 of 14 finished

Non-Completion Rate

14.3%

2 ended early

Currently Active

1

trials recruiting

Total Trials

20

all time

Status Distribution
Active(1)
Completed(12)
Terminated(2)
Other(5)

Detailed Status

Completed12
unknown5
Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (15.0%)
Phase 36 (30.0%)
Phase 49 (45.0%)
N/A2 (10.0%)

Trials by Status

recruiting15%
completed1260%
withdrawn210%
unknown525%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT04133311Phase 3

A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed
NCT04957329Phase 4

Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells

Recruiting
NCT00383019Phase 3

A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).

Completed
NCT00159653Phase 3

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

Completed
NCT00277498Phase 3

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Completed
NCT04743622Phase 4

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost

Completed
NCT00283764Phase 3

Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device

Withdrawn
NCT00143429Phase 2

Corneal Versus Conjunctival Delivery Using a Delivery Device

Withdrawn
NCT04164459Phase 4

Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.

Unknown
NCT02059278Phase 3

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Completed
NCT00798694Phase 4

How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?

Completed
NCT03318146Not Applicable

Safety, Tolerability and Preliminary Efficacy of Unilateral Latanoprost-loaded Punctual Plug -EXP-LP

Unknown
NCT02792803Phase 4

A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma

Unknown
NCT01155219Phase 4

Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.

Completed
NCT01037036Phase 2

A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG

Completed
NCT00468988Phase 4

Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers

Completed
NCT00799682Phase 4

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

Completed
NCT00796198Phase 4

Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure

Unknown
NCT00465621Phase 2

Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed
NCT00440336Not Applicable

Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.

Unknown

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20